Signify Bio Launches with an Oversubscribed $15 Million Initial Financing and Strategic Partnership with UTSW Focused on Nucleic Acid Enabled Protein Therapeutics
Signify Bio, a pioneering biotechnology company harnessing the human body for the production of in situ protein therapeutics, today announced an oversubscribed $15 million initial financing. The round was led by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, a subsidiary of Danaher Corporation, Eli Lilly and Company, and BrightEdge, the American Cancer Society’s (ACS) venture capital arm.